Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jul 2013

Munoz Javier, Schlette Ellen, Kurzrock Razelle

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biopsy, Needle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Chemical Analysis

Share to Indoles

Share to Leukemia, Hairy Cell

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 23733763
DOI: 10.1200/JCO.2012.45.7739

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation.PMID 23733763Read ↗

Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.Semantic proximity Read ↗

Efficacy of vemurafenib in hairy-cell leukemia.Semantic proximity Read ↗

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.Semantic proximity Read ↗

BRAF inhibition in refractory hairy-cell leukemia.Semantic proximity Read ↗

BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials.Semantic proximity Read ↗

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activitySemantic proximity Read ↗

Targetable Mutations in BRAF V600E–Negative Hairy-Cell LeukemiaSemantic proximity Read ↗

[Molecular and therapeutic advances in Hairy cell leukemia].Semantic proximity Read ↗

BRAF V600E mutation in hairy cell leukemia: from bench to bedsideSemantic proximity Read ↗

Non-V600E BRAF mutations and treatment for hairy cell leukemia.Semantic proximity Read ↗

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.Semantic proximity Read ↗

Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.